RANCHO CORDOVA, Calif.,
Sept. 7, 2021 /PRNewswire/
-- ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market
leader in automated cell processing tools and services in the cell
and gene therapy field, today announced that Chris Xu, Ph.D., Chief Executive Officer, will
present a company overview at the H.C. Wainwright 23rd Annual
Global Investment Conference.
If you are an institutional investor and would like to listen to
the company's on-demand presentation, please click on the following
link to register for the conference: www.hcwevents.com. Once your
registration is confirmed, you will be prompted to log into the
conference website to request a one-on-one meeting with the
About ThermoGenesis Holdings, Inc.
Holdings, Inc. develops, commercializes, and markets a range of
automated technologies for CAR-T and other cell-based therapies.
The Company currently markets a full suite of solutions for
automated clinical biobanking, point-of-care applications, and
automation for immuno-oncology, including its semi-automated,
functionally-closed CAR-TXpress™ platform, which streamlines
the manufacturing process for the emerging CAR-T immunotherapy
market. For more information about ThermoGenesis, please
Paula Schwartz, Rx
SOURCE ThermoGenesis Holdings, Inc.